Erytech Pharma : Catalyseur majeur fin 2020 : données intermédiaires de phase 3 pancréas
>Contact société - Nous nous sommes récemment entretenus avec Eric Soyer, CFO d’Erytech, avec qui nous avons fait le point sur l’activité de la société dans le contexte COVID-19. Nous sommes également revenus sur les annonces de la semaine dernière sur l’avancée de TRYbeCA-1.COVID-19: un léger impact, somme toute classique pour une biotech - Nous estimons que pour le secteur biotech, l’impact COVID se matérialisera en grande partie par des retards d’o...Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.